A combination of targeted probes and new imaging technologies provides a powerful set of tools with the potential to improve the early detection of cancer. To develop a probe for detecting colon cancer, we screened phage display peptide libraries against fresh human colonic adenomas for high-affinity ligands with preferential binding to premalignant tissue. We identified a specific heptapeptide sequence, VRPMPLQ, which we synthesized, conjugated with fluorescein and tested in patients undergoing colonoscopy. We imaged topically administered peptide using a fluorescence confocal microendoscope delivered through the instrument channel of a standard colonoscope. In vivo images were acquired at 12 frames per second with 50-lm working distance and 2.5-lm (transverse) and 20-lm (axial) resolution. The fluorescein-conjugated peptide bound more strongly to dysplastic colonocytes than to adjacent normal cells with 81% sensitivity and 82% specificity. This methodology represents a promising diagnostic imaging approach for the early detection of colorectal cancer and potentially of other epithelial malignancies.
A combination of targeted probes and new imaging technologies provides a powerful set of tools with the potential to improve the early detection of cancer. To develop a probe for detecting colon cancer, we screened phage display peptide libraries against fresh human colonic adenomas for high-affinity ligands with preferential binding to premalignant tissue. We identified a specific heptapeptide sequence, VRPMPLQ, which we synthesized, conjugated with fluorescein and tested in patients undergoing colonoscopy. We imaged topically administered peptide using a fluorescence confocal microendoscope delivered through the instrument channel of a standard colonoscope. In vivo images were acquired at 12 frames per second with 50-lm working distance and 2.5-lm (transverse) and 20-lm (axial) resolution. The fluorescein-conjugated peptide bound more strongly to dysplastic colonocytes than to adjacent normal cells with 81% sensitivity and 82% specificity. This methodology represents a promising diagnostic imaging approach for the early detection of colorectal cancer and potentially of other epithelial malignancies.
Colorectal cancer develops in a multistep process that arises from genetic alterations and environmental insults 1 . Most colorectal cancers can be prevented through the detection and removal of premalignant polypoid lesions 2 . Despite the efficacy of endoscopic screening and polyp removal, colorectal cancer remains the third most common cancer in men and women in the United States 3 . This high incidence results from noncompliance with screening guidelines and limitations on conventional endoscopic screening, which lacks molecular specificity and reveals only anatomical changes through a macroscopic view of the surface mucosa. Flat or depressed neoplasms are difficult to detect using endoscopic methods 4 , and patients with chronic inflammatory bowel disease are at increased risk of developing malignancy due to undetected dysplastic lesions 5 . There is therefore a need for improved methods for detecting early changes in high-risk individuals. New approaches that are compatible with conventional endoscopy would allow seamless integration into existing protocols and would be applicable to other cancers of the epithelium, including those of the esophagus, stomach, cervix and bladder, which together result in around 65% of all cancer deaths in the United States 3 .
A number of biomarkers for colorectal cancer have been described that might facilitate surveillance, identification of high-risk populations and earlier detection 6 . Because of their high specificity, antibodies to these markers have been investigated for cancer detection and drug delivery. However, their in vivo use has been limited by immunogenicity and challenges in development and production 7 . By contrast, peptides are typically less immunogenic, nontoxic and relatively simple to produce in quantity. Their small size might also allow them to penetrate more easily into diseased mucosa, potentially binding to molecular targets at greater tissue depths. The identification of peptides for mucosal markers would allow topical administration, which maximizes safety and reduces the risk from immunoreactivity-important considerations for the development of molecular imaging approaches.
Peptide libraries displayed on the surface of bacteriophage are highly diverse libraries that can be screened for specific binding properties 8 . Peptides targeting human colon cancer cell lines have been identified 9 and have been used for delivering radioisotopes 10 or as imaging agents in animal models 11 . However, isolated and cultured cells might de-differentiate and lose tissue-specific traits upon prolonged culture 12 . Cell culture screening protocols might also fail owing to the inaccessibility of relevant receptors in vivo 13 . Intravenous injection of native phage libraries followed by removal of the organs of interest has identified peptides with tissue-specific homing properties in animal models 14 . Although ligands for receptors isolated in animals have been useful for understanding their human homologs, species-specific differences might limit their application in humans 15 . Tissue-homing peptides have also been shown in humans, but the recovery of target tissues after intravenous phage administration is only possible under special circumstances 16 . Notably, the selection of peptides through intravenous administration is biased toward targeting receptors that are directly accessible through the vasculature, facilitating the discovery of molecules that are more suitable for drug delivery to the endothelium than for binding to mucosal surfaces, the object of endoscopy. Successful studies using phage display illustrate a key feature of this technique: it can be highly selective for the tissues to which the library is exposed. Thus, we reasoned that if peptides binding to premalignant human tissues are desired, these tissues should be used in the selection process.
We used an M13 phage library to identify peptides that specifically bind dysplastic colonic mucosa. We first removed nonspecific peptides by clearing with nonmalignant intestinal epithelial cells followed by selection with fresh human colonic biopsies. A peptide that binds colonic dysplasia was identified, synthesized and conjugated with fluorescein for in vivo testing in a pilot study involving patients undergoing routine colonoscopy. We observed fluorescence signals from topically administered peptide using a flexible-fibered confocal microscope (Cellvizio-GI, Mauna Kea Technologies) 17 that can pass through the accessory channel of standard colonoscopes, allowing high-speed image acquisition and assessment of local peptide binding characteristics. Fluorescence images and videos of bound topically administered peptide collected in vivo showed that our selected peptide bound more strongly to dysplastic colonocytes than to the adjacent normal mucosa in the same subject.
RESULTS
Isolation of phage with specific binding to colonic dysplasia Two rounds of incubation with nonmalignant human intestinal cells reduced the original titer of the phage library by 97% to 4.25 Â 10 9 plaque forming units (p.f.u.). Subsequent panning using fresh human colonic tissue further reduced the library to 1.9 Â 10 5 clones. After two rounds of selection, 7.8 Â 10 4 p.f.u. were retained, indicating that around 41% of the phage remained unbound. Histology indicated that tissues in the second round of selection were hyperplastic, inflamed and focal adenoma, so this round of selection was considered a clearing round and we retained the unbound phage. After the third round of selection, about 6,000 p.f.u. remained. Histology revealed that the polyps used in this round were tubular adenomas, so we retained the bound phage for further characterization.
In vitro assays
Of the 40 phage clones we tested, one clone displaying a peptide with sequence VRPMPLQ showed 2-3 times as much fluorescence intensity as control M13 antibody alone. Binding studies indicated that the binding of this peptide to HT-29 human adenocarcinomaderived cells was around 20-fold greater than its binding to Hs738.st/ int nonmalignant human intestinal cells (Fig. 1a) . We saw increased binding compared to ten other randomly selected clones also eluted from the third round of selection. Assays performed using this clone on fresh biopsies of tubular adenoma from human colon polyps yielded threefold greater fluorescence intensity from abnormal colonocytes lining dysplastic crypts than from adjacent normal mucosa (Fig. 1b,c) .
Although we identified a number of peptides using this procedure, the evaluation of selected peptides in clinical studies necessitated choosing one initial peptide. As our goal was to identify a peptide reagent that could target dysplasia in a clinically relevant setting, we synthesized and conjugated the peptide VRPMPLQ with fluorescein for a pilot human study conducted during screening colonoscopy. 
In vivo imaging In vivo imaging of dysplastic colon treated with our peptide showed fluorescence that correlated with areas containing dysplastic colonocytes ( Fig. 2a and Supplementary Fig. 1 online) . By contrast, normal mucosa sprayed with peptide showed decreased fluorescence associated with residual peptide collecting in regions between crypts (Fig. 2b) . Histology confirmed the presence of both dysplastic and normal crypts in the biopsy specimens (Fig. 2c,d ). All peptide fluorescence signals were greater than background autofluorescence ( Supplementary Fig. 2 online) . Peptide also collected in lumens of normal crypts and appeared as round spots of increased fluorescence in the center of a low-fluorescence colonocyte layer. The contrast between adenomatous and normal colonocytes was 17.9 ± 4.2 (s.e.m.), with an average signal-to-noise ratio (SNR) of 9.3 ± 0.9 (s.e.m.), for n ¼ 18 polyps diagnosed as either tubular adenoma or tubulovillous adenoma. The contrast ranged from 0. Imaging of a border between a dysplastic polyp and normal mucosa provided a reference point that controlled for variables such as incubation time and probe contact pressure, which contributes to imaging depth (Fig. 3 and Supplementary Video 1 online) . The contrast between polyp and normal colonocytes calculated at this border region was 22.6 ± 5.7 (s.d.) with an SNR of 17.0 ± 2.5 (s.d.).
In contrast to dysplastic polyps, the fluorescence associated with hyperplastic polyps (n ¼ 5) was predominantly associated with residual peptide collecting in regions between crypts and in crypt lumens. Hyperplastic crypts often had slit-like or stellate-shaped lumens. Fluorescence from an additional four endoscopically polypoid lesions was similar to that of normal mucosa. These specimens were subsequently diagnosed as containing no significant abnormality upon pathological examination.
Imaging using a scrambled control peptide (QLMRPPV) showed no enhanced binding for either dysplastic (n ¼ 5) or hyperplastic (n ¼ 2) polyps relative to normal mucosa. We subsequently confirmed this result using ex vivo frozen sections ( Supplementary Fig. 3 online) . Imaging of dysplastic polyps was similar to that of hyperplastic polyps for scrambled control peptide.
We calculated the fluorescence intensity between adenoma and normal mucosa using mean colonocyte fluorescence signal values, and this yielded an optimum sensitivity of 81% and specificity of 82% for a signal threshold of 6.1, with P o 0.01 using a two-sided Student t-test (Fig. 4) .
We saw no preferential binding for three adenomas, and it was necessary to rinse with water for several seconds before imaging to remove excess peptide, which might contribute to nonspecific fluorescence (Supplementary Table 1 online) . In addition, imaging performed after B10 min (owing to difficulty in positioning the probe or subject peristalsis) yielded substantially decreased fluorescence signal. We observed photobleaching during the imaging procedure on rare occasions when the probe was held stationary on the tissue surface for more than 5 s. We saw no toxicity associated with peptide administration in any subject (Supplementary Table 2 online).
DISCUSSION
New endoscopic imaging techniques such as optical coherence tomography (OCT) 18 , autofluorescence imaging (AFI) 19, 20 , and narrowband imaging (NBI) 21 have been investigated for the detection of dysplasia in the gastrointestinal tract. Fluorescent imaging in combination with 5-aminolevulinic acid (5-ALA) 22 , as well as fluorescently labeled monoclonal antibodies, have also been investigated 23, 24 . It has been reported that endoscopic confocal microscopy with systemically administered fluorescein has advantages over locally applied contrast agents such as acriflavine 25 . However, these nonspecific dyes provide anatomical and not functional data and are complementary to approaches that target molecular markers of disease. The combination of targeted peptide probes and visualization using confocal microendoscopy offers a new method for facilitating in vivo optical imaging for early cancer detection. We performed peptide selection using freshly excised tissue, which mimics the colonic environment as closely as is experimentally feasible, to identify peptides that bind to mucosal surface markers of colonic dysplasia. Pilot in vivo human studies showed that at least one of these peptides, VRPMPLQ, shows selective binding to dysplastic tissue over normal mucosa. Imaging performed using a flexible-fibered confocal microscope showed up to 50 times more fluorescence due to peptide binding to dysplastic polyps than to normal mucosa. In vivo imaging was performed at a 50-mm working distance, enabling us to image through the surface layer and visualize peptide binding to crypt colonocytes as confirmed by histopathology. Although this peptide currently does not improve on the reported performance of endoscopic confocal microscopy using intravenously administered fluorescein 25 , intravenously administered agents are less practical for clinical use as a screening tool. Peptides, as well as other targeted molecular probes, have the potential to provide quantitative in vivo measures and molecular subtyping of dysplasia for directed therapy with minimal subjective interpretation. They might also serve to mark tumor margins and thereby improve tissue removal.
The range in contrast values between individuals in our study indicates that variations in mucus consistency and bowel cleanliness, as well as biological variations between subjects, might affect the performance of this approach. The process of applying and washing specific probes is expected to improve as the technique is used in more subjects. Dysplasia-modified mucins might also be viable targets for peptide reagents. A number of membrane-bound and secreted mucins are differentially expressed in colon adenocarcinomas, and these might serve as targets, given the presence of mucin in our intact tissue-panning specimens 26 . In addition, the absence of a particular inhibitory molecule 27 , or alterations in tight junction structure in dysplastic tissue 28 , might allow peptides to bind to previously inaccessible sites. Therefore, reagents discovered through intact tissue panning might have the advantage of selecting for targets that are not differentially expressed, but are clinically relevant because of accessibility.
The molecular target of the VRPMPLQ peptide is unknown and the sequence does not show full homology to ligands for known receptors. This peptide does have partial homology (6 of 7 amino acids, V/LRPMPLQ) to the laminin-G domain of contactin-associated protein 1 (Caspr-1), which is present in human intestine and might be involved in contactin-mediated cell signaling and in tumor metastasis and invasion 29, 30 . Given the short amino acid sequences of the candidate peptides, however, homology is of limited predictive value. Several peptides, each targeted towards a different molecular marker, might be required to optimize sensitivity and specificity for detecting dysplasia. Additional biopsy-screened phage are therefore being characterized.
The use of a targeted contrast agent for screening would ideally involve an instrument capable of wide-area surveillance used in combination with microscopic high-resolution detection. Currently available prototype fluorescence endoscopes measure bulk tissue fluorescence, are low in resolution, and tend to wash out contrast from peptide binding owing to considerable autofluorescence background. This study used the real-time microstructural information provided by confocal microendoscopy to validate peptide binding, which provides a powerful adjunct to macroscopic imaging. Future wide-area imaging using targeted peptide reagents could be performed by modifying current prototype fluorescence endoscopic systems to excite and collect longer wavelengths. The identification of dysplasiatargeting peptides might substantially enhance efforts to detect premalignant lesions in patients with inflammatory bowel diseases or Barrett's esophagus, conditions for which the in vivo assessment of risk is currently challenging. This methodology could also be developed for detecting other epithelial cancers, assessing disease margins during interventional procedures, monitoring biomarkers for the progression and recurrence of disease, and facilitating targeted drug delivery.
METHODS
Panning with excised tissue. We selected peptides that preferentially bound to dysplasia through several rounds of clearing with cell lines and normal tissue and panning with dysplastic polyps (Fig. 5) . The first round of panning was performed using a cleared library from which nonspecifically bound phage was removed using Hs738.st/int cells (Supplementary Methods online). We performed clearing with biopsies of normal mucosa before each selection step to reduce nonspecifically binding phage before panning with intact polyps from the same individual. We chose this procedure to bias selection towards markers that were present only on dysplastic mucosa rather than those that were overexpressed, with the intention of optimizing fluorescence signal-to-background during endoscopic imaging. All polyps used for panning were subsequently stained using hematoxylin and eosin (H&E) and read by two pathologists independently.
Cell-binding assays. Of the roughly 6,000 phage eluted from adenomas in the third round of selection, we randomly selected 40 to be tested using HT-29 cells. We performed imaging on four pools of ten phage clones, and one pool was split into ten individual clones for further testing. After antibody incubation with M13 monoclonal antibody conjugated with FITC (Fitzgerald Industries), cells were imaged with a fluorescence confocal microscope (Leica TCS SP2). We used increased fluorescence intensity as an indicator of phage binding to select the most promising phage clone for further assays. We amplified and assessed this most promising phage clone plus ten additional randomly selected clones from the third round of panning. We determined preferential binding to HT-29 cells over Hs738.st/int cells by measuring the titer of bound phage relative to wild-type insertless phage used as a control. 
Clone and characterize
Ex vivo imaging of phage binding. In addition to cell binding assays, the 40 clones above were also assessed in pools and then as individual clones for binding to intact biopsy specimens. Fresh biopsies were rinsed in fresh DMEM, then incubated for 15 min at room temperature with 5 Â 10 9 p.f.u. phage in 300 ml DMEM. Biopsies were then rinsed twice with PBS, blocked using 1% BSA for 5 min, rinsed again with PBS, and incubated with 300 ml of 1:1,000 mouse M13 monoclonal antibody conjugated with FITC for 1 h at room temperature. After antibody incubation, biopsies were rinsed twice with PBS and imaging was performed using a commercial confocal microscope (Bio-Rad MRC-1024) at magnifications of Â10-Â60. All biopsies were subsequently formalin-fixed, H&E-stained, and read by staff pathologists at the Palo Alto VA Hospital.
Human study. IRB approval was granted by Stanford University Medical Center and the VA Palo Alto Health Care Systems. We recruited individuals undergoing routine screening colonoscopy and obtained informed consent from all individuals. Polyps that were identified endoscopically during routine colonoscopy were washed with water for B5 s to remove excess mucus. Approximately 3-6 ml of peptide at a concentration of 100 mM was then administered topically to 1-2 cm 2 of the surface of the colon using a standard endoscopic spray catheter. Excess peptide was removed by gently rinsing the region with water. Imaging was performed within B5 min of peptide administration using the Cellvizio-GI confocal fluorescence imaging system (Mauna Kea Technologies). The fibered confocal microscope was passed through the instrument channel of a standard colonoscope (Olympus CFQ-160). Imaging of the polyp and adjacent endoscopically normal-appearing mucosa was performed before and after peptide administration. After imaging, the polyp was removed according to standard protocol, submitted for routine histology, and analyzed by staff pathologists at the Palo Alto VA Hospital.
Image and statistical analysis. For each polyp and normal region imaged in vivo, we selected five representative images according to the following criteria: minimum motion artifact; probe dwell time of less than 2 s; lack of stool or excess mucus preventing contact with the mucosa; and recognizable crypt structure in the images. We calculated fluorescence signal intensity by taking the mean of a pixel array corresponding to a 25 Â 25 mm square region within the colonocyte layer for three sites within each image. The signal noise was calculated by taking the standard deviation (s.d.) of the values in this pixel array. The fluorescence contrast was obtained from the ratio of the mean polyp fluorescence intensity to the mean normal fluorescence intensity over all sites within each subject. The SNR was obtained from the ratio of the mean of the polyp signal to signal noise for each site within each subject. Average fluorescence signal contrast and SNR attributed to the peptide were then calculated by averaging the values obtained for each subject. Standard errors of the mean (s.e.m.) were reported based on n ¼ 18 polyps. The receiver operating characteristic (ROC) for adenoma versus normal was calculated using mean fluorescence signal values for each image site using n ¼ 270 values for adenoma and n ¼ 270 values for normal.
Note: Supplementary information is available on the Nature Medicine website.
